<div><p>A fundamental challenge for developing an effective and safe HIV-1 vaccine is to identify vaccine immunogens that can initiate and maintain immune responses leading to elicitation of broadly neutralizing HIV-1 antibodies (bnAbs) through complex maturation pathways. We have previously found that HIV-1 envelope glycoproteins (Env) lack measurable binding to putative germline predecessors of known bnAbs and proposed to search for non-HIV immunogens that could initiate their somatic maturation. Using bnAb b12 as a model bnAb and yeast display technology, we isolated five (poly)peptides from plant leaves, insects, <i>E</i>. <i>coli</i> strains, and sea water microbes that bind to b12 putative germline and intermediate antibodies. Rabbit ...
b12, one of the few broadly neutralizing antibodies against HIV-1, binds to the CD4 binding site (CD...
b12, one of the few broadly neutralizing antibodies against HIV-1, binds to the CD4 binding site (CD...
SummaryBroadly neutralizing antibodies (bnAbs) directed to the V2 apex of the HIV envelope (Env) tri...
A fundamental challenge for developing an effective and safe HIV-1 vaccine is to identify vaccine im...
A fundamental challenge for developing an effective and safe HIV-1 vaccine is to identify vaccine im...
Development of effective vaccines against mutable viruses (i.e HIV-1 and influenza) remains a big ch...
Several human monoclonal antibodies (hmAbs) and antibody fragments, including the best characterized...
Several human monoclonal antibodies (hmAbs) and antibody fragments, including the best characterized...
After over 35 years of research, a prophylactic HIV vaccine remains elusive. However, the discovery ...
An effective HIV-1 vaccine will likely elicit broadly neutralizing antibodies (bnAbs). However, deve...
After over 35 years of research, a prophylactic HIV vaccine remains elusive. However, the discovery ...
The high viral diversity of HIV-1 is a formidable hurdle for the development of an HIV-1 vaccine. El...
Broadly neutralizing antibodies (bnAbs) against human immunodeficiency virus (HIV)-1 are rare in nat...
b12, one of the few broadly neutralizing antibodies against HIV-1, binds to the CD4 binding site (CD...
Development of new immunogens eliciting broadly neutralizing antibodies (bNAbs) is a main priority f...
b12, one of the few broadly neutralizing antibodies against HIV-1, binds to the CD4 binding site (CD...
b12, one of the few broadly neutralizing antibodies against HIV-1, binds to the CD4 binding site (CD...
SummaryBroadly neutralizing antibodies (bnAbs) directed to the V2 apex of the HIV envelope (Env) tri...
A fundamental challenge for developing an effective and safe HIV-1 vaccine is to identify vaccine im...
A fundamental challenge for developing an effective and safe HIV-1 vaccine is to identify vaccine im...
Development of effective vaccines against mutable viruses (i.e HIV-1 and influenza) remains a big ch...
Several human monoclonal antibodies (hmAbs) and antibody fragments, including the best characterized...
Several human monoclonal antibodies (hmAbs) and antibody fragments, including the best characterized...
After over 35 years of research, a prophylactic HIV vaccine remains elusive. However, the discovery ...
An effective HIV-1 vaccine will likely elicit broadly neutralizing antibodies (bnAbs). However, deve...
After over 35 years of research, a prophylactic HIV vaccine remains elusive. However, the discovery ...
The high viral diversity of HIV-1 is a formidable hurdle for the development of an HIV-1 vaccine. El...
Broadly neutralizing antibodies (bnAbs) against human immunodeficiency virus (HIV)-1 are rare in nat...
b12, one of the few broadly neutralizing antibodies against HIV-1, binds to the CD4 binding site (CD...
Development of new immunogens eliciting broadly neutralizing antibodies (bNAbs) is a main priority f...
b12, one of the few broadly neutralizing antibodies against HIV-1, binds to the CD4 binding site (CD...
b12, one of the few broadly neutralizing antibodies against HIV-1, binds to the CD4 binding site (CD...
SummaryBroadly neutralizing antibodies (bnAbs) directed to the V2 apex of the HIV envelope (Env) tri...